Published on 09/12/2025

System Suitability and Quality Controls for E&L Methods

Introduction to Extractables and Leachables (E&L)

In the pharmaceutical industry, the integrity of drug product quality is paramount. A critical aspect of ensuring this integrity involves the evaluation of extractables and leachables (E&L) from packaging materials and single-use systems. E&L testing helps to assess potential contaminants that could affect product safety and efficacy. Regulatory bodies such as the FDA, EMA, and MHRA provide guidance outlining the necessity for systematic approaches to E&L risk assessments.

This article serves as a comprehensive guide on establishing system suitability and quality controls for E&L methods, focusing on analytical evaluation thresholds (AET), dose-based thresholds (DBT), container closure integrity (CCI), and validation practices for single-use systems.

Understanding AET and DBT

Establishing appropriate AET and DBT values is crucial for effective E&L evaluation. These thresholds are utilized to determine which extractable or leachable compounds pose a risk to products. Here’s a step-by-step process to define AET and DBT:

• Step 1: Identify the Product and Packaging: Understand the drug product characteristics, its administration route, and packaging materials (e.g., elastomers, plastics).
• Step 2: Define the AET: The analytical evaluation threshold (AET) is defined based on toxicological assessments and the intended use of the product. This value serves as the threshold above which extractables should be quantified and characterized.
• Step 3: Implement DBT Calculations: The dose-based threshold (DBT) is based on the maximum daily dose of the drug. It is calculated using a defined equation to ensure that any leachable’s concentration falls below what is considered safe, often expressed as a percentage of the daily dose.
• Step 4: Risk Assessment: Conduct a thorough E&L risk assessment to consider potential toxicological effects of each substance present. This could include information derived from literature, available toxicity data, or historical data regarding similar products.

Both AET and DBT must be documented meticulously as part of the E&L testing protocol, in compliance with the ICH guidelines and other relevant regulatory frameworks.

Establishing Quality Control Parameters for E&L Testing

Quality control (QC) is essential to ensure that the E&L testing process is robust and defensible. Quality controls should be implemented at each stage of the E&L analysis, as follows:

• Step 1: Selection of Analytical Methods: Choose appropriate analytical techniques for E&L testing, such as GC-MS, LC-MS, or HPLC. Method suitability should be established based on sensitivity and specificity requirements for the expected leachables.
• Step 2: Calibration of Equipment: Ensure that all analytical instruments are calibrated according to the manufacturer’s specifications. Perform routine maintenance to ensure compliance with cGMP practices.
• Step 3: Standard Operating Procedures (SOPs): Develop and maintain SOPs for E&L testing. Ensure these SOPs cover sample preparation, analytical methods, and data interpretation.
• Step 4: Positive and Negative Controls: Utilize both positive and negative controls during testing to confirm the validity of the analytical method. This will help ascertain the accuracy and reliability of the E&L results.

Quality control measures must align with the EU GMP Annex 1 expectations as well as other guidelines laid out by regulatory bodies, ensuring that any E&L testing performed is inspection-ready.

Container Closure Integrity (CCI) Assessment

Ensuring the integrity of container closures is pivotal in preventing contamination and maintaining drug product stability. Here’s how to establish effective CCI testing methodologies:

• Step 1: Define CCI Standards: Determine the acceptable CCI thresholds based on product stability and storage conditions. Requirements vary with different drug formulations and intended use.
• Step 2: Choose Testing Methods: Various methods are available for CCI testing, including vacuum decay, dye ingress, and microbial challenge testing. Select methods appropriate for the specific product under examination.
• Step 3: Testing Protocol Development: Draft detailed protocols for conducting CCI tests, which includes sample size, environmental conditions, and frequency of testing.
• Step 4: Results Analysis and Documentation: Collect and interpret data carefully to ensure that results are in compliance with established CCI acceptance criteria. Document everything for regulatory purposes.

As per the USP CCI guidance, CCI assessments are integral to analyzing how well packaging protects the product throughout its shelf life. Regular audits and reviews can further reinforce CCI practices.

Single-Use Systems Validation

Single-use systems (SUS) have become increasingly popular due to reduced cross-contamination risks and minimized cleaning requirements. However, their validation poses unique challenges. Follow these steps to achieve effective validation of single-use systems:

• Step 1: Component Assessment: Evaluate the materials and components used in the SUS. Analyze their compatibility with drug products and assess any potential for extractables and leachables that could impact safety.
• Step 2: Develop Validation Protocols: Design validation protocols to confirm that single-use systems function as intended. Include tests for performance, sterility, and potential leachables that could contaminate the product.
• Step 3: Execute the Validation: Conduct the validation testing in accordance with established protocols. Document all findings, deviations, and corrective actions taken during the validation process.
• Step 4: Continuous Monitoring: After initial validation, implement continuous monitoring practices to ensure long-term system suitability. Re-evaluate systems periodically or whenever changes occur.

Compliance with ongoing regulations and guidance from organizations such as the PQRI is essential to maintain the integrity of the single-use systems in pharmaceutical manufacturing.

Conclusion

The need for rigorous E&L assessment through systematic testing is integral to safeguarding pharmaceutical products. Adopting best practices for AET, DBT, CCI assessments, and validation of single-use systems ensures compliance with prevailing regulations in the US, UK, and EU. By following the outlined steps, pharmaceutical professionals can improve product safety and maintain quality across the supply chain.